HERE And Sigfox Join Forces to Create Global IoT Location Service for Logisitics and Supply Chain Sectors
30.5.2018 15:11:00 EEST | Business Wire | Press release
HERE Technologies and Sigfox today announced a partnership to develop and deploy a global location service that will open new opportunities for IoT applications, particularly in supply chain and logistics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180530005612/en/
By integrating global coverage of wifi hotspots from HERE with the Sigfox worldwide network and geolocation engine, industry and consumers will be able to locate their assets everywhere, both indoors (including inside factories warehouses and other buildings) and outdoors, without any additional infrastructure, regardless of the size and quantity of assets.
The use of IoT asset tracking solutions in the global supply chain and logistics sector could create $1.9 trillion of economic value, according to Cisco and DHL, the world’s largest logistics provider. Current Real Time Location Services (RTLS) solutions are not always viable due to the high cost sensitivity and the short battery life constraints. This partnership also expands asset tracking opportunities for companies that could not previously afford geolocation services. The unique combination of both HERE and Sigfox technologies and their worldwide footprint enables clients to not only locate their assets, but to collect useful data that will help them to optimize their flows, ensure better transport conditions and increase service reliability. Use cases currently in live phase include air transport, luggage/trolley management, location of stolen/missing cars cars, industrial asset management and location of shipping containers.
«Our partnership with Sigfox reinforces HERE as a major player in IoT» said Christophe Hamaide, Senior Account Executive at HERE. « The HERE Location Suite references billions of Wi-Fi hotspots, and through this joint initiative, we will be able to pinpoint the location of millions of connected objects all around the world in the coming years. »
“This partnership is another major step to accomplish Sigfox’s ambitious vision to become the most competitive provider of industrial data in IoT” said Laetitia Jay, Chief Marketing Officer at Sigfox. “Locating assets while guaranteeing the lowest total cost of ownership of the solution is a key driver for logistics and supply chain industry to benefit from massive IoT business impact.”
For more information on Sigfox, visit Twitter or LinkedIn.
For more information on HERE Technologies, visit www.here.com
* http://www.businessinsider.fr/us/asset-tracking-in-the-supply-chain-and-logistics-2016-9
About Sigfox
Sigfox is the world’s leading IoT service
provider thanks to its global network that connects billions of devices
to the Internet while consuming as little energy as possible, as simply
as possible. Sigfox’s unique approach to device-to-cloud communications
addresses the three greatest barriers to global IoT adoption: cost,
energy consumption, and global scalability.
Today, the network is present in 45 countries and on track to cover 60 by 2018. With millions of objects connected and a rapidly growing partner ecosystem, Sigfox empowers companies to move their business model towards more digital services. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in Labège near Toulouse, France’s “IoT Valley”. Sigfox also has offices in Paris, Madrid, Munich, Boston, San Francisco, Dubai, Singapore, Sao Paulo and Tokyo.
About HERE Technologies
HERE, the Open Location Platform
company, enables people, businesses and cities to harness the power of
location. By making sense of the world through the lens of location we
empower our customers to achieve better outcomes – from helping a city
manage its infrastructure or a business optimize its assets to guiding
drivers to their destination safely. To learn more about HERE, including
our new generation of cloud-based location platform services, visit http://360.here.com
and www.here.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180530005612/en/
Contact information
Media Contacts:
Sigfox – Elan Edelman
sigfoxfrance@elanedelman.com
Pauline
Persyn - 06 20 43 84 67
Luisa Vittadini - 01 86 21 50 51
or
HERE
- Agence AxiCom
Constance Falourd – 01 56 02 68 25
constance.falourd@axicom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom